Risk group | Cost per DALY (excluding asthma) | Cost per DALY (including asthma) | Palivizumab price to achieve cost-Effectiveness (including asthma) | % decrease in Palivizumab Price | |
---|---|---|---|---|---|
50 mg Vial b | 100 mg Vial c | ||||
CHD | $266,020 | $218,968 | $278 | $512 | 46.5% |
CLD | $472,139 | $287,057 | $270 | $497 | 48.1% |
<29 | $585,537 | $226,900 | $329 | $605 | 36.8% |
29–32 | $685,961 | $347,593 | $237 | $436 | 54.5% |
33–36 | $2,092,809 | $1,149,584 | $87 | $160 | 83.3% |
No risk | $7,503,953 | $3,023,294 | $31 | $57 | 94.0% |